<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1557">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01999400</url>
  </required_header>
  <id_info>
    <org_study_id>FDA-SOL-1120920</org_study_id>
    <secondary_id>HHSF223201300460A</secondary_id>
    <secondary_id>HHSF223201000082C</secondary_id>
    <nct_id>NCT01999400</nct_id>
  </id_info>
  <brief_title>Correlation of Mesalamine Pharmacokinetics With Local Availability</brief_title>
  <official_title>Correlation of Mesalamine Pharmacokinetics With Local Availability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to provide data to the FDA correlating pharmacokinetics with local
      availability of medications within the gastrointestinal tract.  This study will support the
      establishment of scientifically based standards for evaluating drugs which act locally
      within the gastrointestinal tract.  Specific objectives of this study are to: (1) quantify
      how the plasma concentrations of mesalamine, an agent used to treat inflammatory bowel
      disease, are correlated with the concentrations in gastrointestinal fluids; and (2) improve
      the physiologically based models for drug absorption from the intestine.  Information from
      this study in concert with in vitro dissolution data will be used to evaluate in vivo-in
      vitro correlation (IVIVC) for concentrations in plasma and intestinal lumen and dissolution
      of mesalamine products.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>concentration of mesalamine and metabolite (N-acetyl-mesalamine) in plasma</measure>
    <time_frame>see Description</time_frame>
    <safety_issue>No</safety_issue>
    <description>0, 0.5, 1, 2, 3, 4, 6, 7, 8, 10, 12, 24, 48, 72 hours after dose of Pentasa or Apriso; 0, 0.5, 1, 2, 3, 4, 6, 7, 8, 10, 12, 24, 48, 72, 96 hours after dose of Lialda; 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours after dose of Asacol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration of mesalamine and metabolite (N-acetyl-mesalamine) in urine</measure>
    <time_frame>see Description</time_frame>
    <safety_issue>No</safety_issue>
    <description>0-8, 8-12, 12-24, 24-48, 48-72 hours after dose of Pentasa or Apriso; 0-8, 8-12, 12-24, 24-48, 48-72, 72-96 hours after dose of Lialda; 0-4, 4-8, 8-12, and 12-24 hours after dose of Asacol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration of mesalamine and metabolite (N-acetyl-mesalamine) in feces</measure>
    <time_frame>see Description</time_frame>
    <safety_issue>No</safety_issue>
    <description>0-12, 12-24, 24-48, 48-72 hours after dose of Pentasa or Apriso; 0-12, 12-24, 24-48, 48-72, 72-96 hours after dose of Lialda</description>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration of mesalamine and metabolite (N-acetyl-mesalamine) in gastrointestinal fluid</measure>
    <time_frame>see Description</time_frame>
    <safety_issue>No</safety_issue>
    <description>0, 1, 2, 3, 4, 5, 6, 7 hours after dose of Pentasa, Apriso, or Lialda</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pH of gastrointestinal fluid</measure>
    <time_frame>see Description</time_frame>
    <safety_issue>No</safety_issue>
    <description>0, 1, 2, 3, 4, 5, 6, 7 hours after dose of Pentasa, Apriso, or Lialda</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Local Drug Concentration in Gastrointestinal Tract</condition>
  <arm_group>
    <arm_group_label>Pentasa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentasa 500 mg capsule x 2 with 240 mL water, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apriso</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apriso 375 mg capsule x 3 with 240 mL water, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lialda</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lialda 1200 mg tablet x 1 with 240 mL water, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asacol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asacol 400 mg tablet x 1 with 240 mL water, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentasa 500 mg capsule x 2 with 240 mL water; single dose</intervention_name>
    <arm_group_label>Pentasa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apriso 375 mg capsule x 3 with 240 mL water; single dose</intervention_name>
    <arm_group_label>Apriso</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lialda 1200 mg tablet x 1 with 240 mL water; single dose</intervention_name>
    <arm_group_label>Lialda</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asacol 400 mg tablet x 1 with 240 mL water; single dose</intervention_name>
    <arm_group_label>Asacol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Adults age 18 to 55.

          2. Male or female voluntarily able to give informed consent.

          3. Body mass index (BMI) 18.5 to 35.

        Exclusion Criteria

          1. Adults unable to consent for themselves or mentally incapacitated.

          2. Prisoners.

          3. Significant clinical illness within 3 weeks prior to Screening.

          4. Use of concomitant medications within 2 weeks prior to receiving study drug,
             including but not limited to prescription drugs, herbal and dietary supplements, over
             the counter medications, and vitamins.  Oral contraception is permitted.

          5. History of gastrointestinal surgery.

          6. History of allergy to non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the
             ingredients of Asacol, Pentasa, Apriso, or Lialda.

          7. History of severe allergic diseases including drug allergies, with the exception of
             seasonal allergies.

          8. Any other factor, condition, or disease, including, but not limited to,
             cardiovascular, renal, hepatic, or gastrointestinal disorders that may, in the
             opinion of the Investigator, jeopardize the safety of the patient or impact the
             validity of the study results.

          9. History of drug addiction or alcohol abuse within the past 12 months.

         10. Pregnant or lactating females.

         11. Surgery within the past 3 months.

         12. Received an investigational drug within 60 days prior to receiving the study drug.

         13. Any clinically significant abnormal lab values during Screening.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duxin Sun, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan, College of Pharmacy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lionberger RA. FDA critical path initiatives: opportunities for generic drug development. AAPS J. 2008;10(1):103-9. doi: 10.1208/s12248-008-9010-2. Epub 2008 Feb 20. Review.</citation>
    <PMID>18446510</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 25, 2013</lastchanged_date>
  <firstreceived_date>November 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Duxin Sun</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
